Search
Now showing items 1-2 of 2
Post-market quality of Rifampicin containing fixed-dose combinations of anti-tuberculosis drugs in Kampala, Uganda
(Makerere University, 2010-08)
Background:
Tuberculosis (TB) is an important curable infectious disease in Uganda; its treatment however is facing a challenge of increasing drug resistance. Although Rifampicin containing Fixed-Dose Combination (R-FDC) ...
In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype
(The British Pharmacological Society, 2010)
AIMS
This study aimed to test whether a pharmacokinetic simulation model
could extrapolate nonclinical drug data to predict human efavirenz
exposure after single and continuous dosing as well as the effects of
concomitant ...